TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02022124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microcrystalline cellulose (open-label inert substance)
Description: The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
Study: NCT03812757

Intervention type: DIAGNOSTIC_TEST
Intervention: Supraclavicular fossa US scanning
Description: As previously stated.
Study: NCT06603805

Intervention type: PROCEDURE
Intervention: MAST group

Intervention type: PROCEDURE
Intervention: breast-conserving surgery plus adjuvant radiotherapy
Description: Patients with early-stage (stage I, stage II, T≤2), and having the willingness to receive BCS were treated with BCS. All patients with BCS received post-surgery radiotherapy. Radiotherapy was administrated with a prescribed dose of 40 Gy in 15 fractions with photons and a boost of 10-16 Gy in 5-8 fractions with electrons to the ipsilateral breast. If axillary lymph nodes were involved, a conventional fraction was delivered with a prescribed dose of 50 Gy in 25 fractions to the ipsilateral breast and draining lymph node regions.
Study: NCT04671017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VLA2001
Description: whole virus inactivated SARS-CoV-2 vaccine adjuvanted with cytosine phospho-guanine (CpG) 1018 in combination with aluminium hydroxide
Study: NCT04195841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Z shaped incision
Description: After local anaesthesia, a mucoperiosteal flap will be elevated at the edentulous ridge with two horizontal incisions placed with a no MB 69 blade, 1-2 mm away from the papilla of the teeth adjacent to the edentulous space following the mesial and distal contour of the teeth. The extend of the incisions should be up to the proximal line angles of the adjacent teeth. These two horizontal incisions are then connected by an oblique incision from the disto-buccal to mesio lingual point angles. A periosteal elevator is used to elevate a full thickness mucoperiosteal flap buccally and lingually to the level of the mucogingival junction, exposing the alveolar ridge of the implant surgical sites.~Endosseous implant placement is done followed by simple interrupted resorbable sutures

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: H shaped incision
Description: After local anaesthesia, a mucoperiosteal flap is elelevated by placing sulcular incisions placed in the proximal sides of the adjacent tooth facing the edentulous space in a bucco lingual direction extending between the proximal line angles using a MB 69 blade.~Mid crestal incision performed in the attached mucosa of the edentulous area connecting the sulcular incisions of the adjacent teeth from the distal to mesial tooth. A full thickness mucoperiosteal flap will be elevated buccally and lingually to the level of the mucogingival junction to expose the alveolar ridge of the implant surgical sites using a periosteal elevator.~Endosseous implant will be placed, followed by simple interrupted resorbable sutures.
Study: NCT04567992

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: superficial cervical plexus block
Description: ultrasound guided injection of local anaesthesia in the superficial cervical plexus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: superficial cervical plexus block
Description: ultrasound guided injection of local anaesthesia in the superficial cervical plexus
Study: NCT01780740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
Study: NCT02080598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 cigarettes in 15 minutes
Study: NCT02734459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery
Description: the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery.
Study: NCT02565368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg
Description: single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg
Description: single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-395 0.5/1000mg
Description: single oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-395 0.5/1000mg
Description: single oral administration
Study: NCT03405194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elvitegravir, Cobicistat, TAF, FTC
Description: Started on day of HIV diagnosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz, TDF, and 3TC
Description: Started on day of HIV diagnosis
Study: NCT04289064

Intervention type: DEVICE
Intervention: Taking a fundus image
Description: The participant only needs to take a fundus image as usual.
Study: NCT00892099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: 50,000 IU tablet given weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: 50,000 IU tablet given monthly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo equivalent of ergocalciferol, given weekly as one tablet
Study: NCT03469453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Delivered Cognitive Behavioral Therapy
Description: Therapist-supported CBT delivered online.
Study: NCT02656771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echo Bi-Metric
Description: The insertion of the Echo® Bi-Metric® THA stem
Study: NCT02415413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study: NCT04430816

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double mesh modification of chevrel's technique
Description: repair of midline incisional hernia by double mesh modification of chevrel's technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: on lay mesh hernioplasty
Description: repair of midline incisional hernia by online mesh hernioplasty
Study: NCT02767414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respirio Flu Test
Description: The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eLab Flu Test
Description: The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
Description: Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
Study: NCT04949997

Intervention type: OTHER
Intervention: diagnose
Description: HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.
Study: NCT00846976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 200mg daily
Study: NCT01704209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibroblast Treatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study: NCT04652752

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONNETTIVINA HI TECH patch
Description: It is a medical device for topical application in the form of a patch with adhesive transparent polyurethane edge and a central pad impregnated with a solution of hyaluronic acid sodium salt, able to create a hydrating environment, such as to favor the natural healing process of tissue repair in case of bruises, abrasions, small cuts, superficial wounds, burns
Study: NCT01449968

Intervention type: OTHER
Intervention: home visit
Description: home visit of UMG

Intervention type: OTHER
Intervention: telephone management
Description: telephone management of the situation reported by the patient's GP
Study: NCT00807001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: oral dose, active or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: oral dose, active or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: oral dose, active or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX184
Description: oral dose, active or placebo
Study: NCT04585126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermediate cervical block
Description: Local anesthesia performed in addition to the general anesthesia
Study: NCT03881852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-12 (Reboxetine)
Description: Dosed orally, twice daily for up to 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosed orally, twice daily for up to 3 weeks
Study: NCT04411498

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibromyalgia diagnosis in patients with SSc
Description: American College of Rheumatology (ACR) FMS diagnostic criteria set:It is evaluated by the common pain index \[WPI\] and symptom severity (SS) scale \[19\]. Diffuse pain index \[WPI\]; It is a scale that can be scored between 0-19 and obtained by indicating the aching regions of the patient during the last 1 week. Right shoulder, left shoulder, right hip \[gluteal region\], left hip \[gluteal region\], left chin, right chin, left upper arm, left lower arm, right upper arm, right lower arm, left upper leg, left lower leg, includes right upper leg, right lower leg, chest, neck, abdomen, upper back, lower back. Symptom Severity Scale \[SSS\]; evaluates weakness, tired awakening and cognitive functions. In addition, muscle pain, weakness, irritable bowel syndrome, memory problems, headache, abdominal pain, numbness, dizziness, insomnia, depression, constipation, irritability, dry mouth etc. It also evaluates somatic symptoms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibromyalgia diagnosis in patients with SSc
Description: American College of Rheumatology (ACR) FMS diagnostic criteria set:It is evaluated by the common pain index \[WPI\] and symptom severity (SS) scale \[19\]. Diffuse pain index \[WPI\]; It is a scale that can be scored between 0-19 and obtained by indicating the aching regions of the patient during the last 1 week. Right shoulder, left shoulder, right hip \[gluteal region\], left hip \[gluteal region\], left chin, right chin, left upper arm, left lower arm, right upper arm, right lower arm, left upper leg, left lower leg, includes right upper leg, right lower leg, chest, neck, abdomen, upper back, lower back. Symptom Severity Scale \[SSS\]; evaluates weakness, tired awakening and cognitive functions. In addition, muscle pain, weakness, irritable bowel syndrome, memory problems, headache, abdominal pain, numbness, dizziness, insomnia, depression, constipation, irritability, dry mouth etc. It also evaluates somatic symptoms.
Study: NCT02575638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CZ48
Description: CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
Study: NCT01803607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: odanacatib
Description: odanacatib 50 mg oral tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo to odanacatib
Description: dose-matched placebo to odanacatib, oral tablet
Study: NCT04289974

Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib (125 mg PO qDay for Days 1-21 of each 28-day cycle) combined with Fulvestrant (500 mg IM on Days 1, 15, and 29, and then once monthly thereafter)
Study: NCT03497195

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening at community level
Description: comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Screening at community level
Description: comparison of chest x-ray and Xpert Ultra versus CRP and Xpert Ultra for active community based screening
Study: NCT04114318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task cognitive-cycling training
Description: Cognitive and cycling training simultaneously for dual-task cognitive-cycling training; stationary bicycle exercise training for single-task cycling training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-task cognitive-cycling training
Description: Cognitive and cycling training simultaneously for dual-task cognitive-cycling training; stationary bicycle exercise training for single-task cycling training
Study: NCT01550224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: An alkylating agent administered for induction per standard of care at 200 mg/m²/day for 7days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: A synthetic hydroxamic acid derivative with antineoplastic activity administered for both groups at 500 mg orally 3 times daily for 3 days prior to Temozolomide 200 mg/m²/day.
Study: NCT02955173

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Laparoscopic or open surgery for resection of gastric or rectal cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Laparoscopic or open surgery for resection of gastric or rectal cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Laparoscopic or open surgery for resection of gastric or rectal cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Laparoscopic or open surgery for resection of gastric or rectal cancer
Study: NCT01308177

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ecabet
Description: comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ecabet
Description: comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
Study: NCT03874988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion-Controlled Meals
Description: Participants will receive portion-controlled meals with the aim of encouraging weight loss and healthier eating.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Self-Monitoring
Description: Participants will be encouraged to track their physical activity, food intake, and weight using technology that will be provided as part of the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GLB-SCI
Description: Participants will take part in a lifestyle intervention program (tailored for spinal cord injury needs) that encourages steady weight loss through increased physical activity and healthier diet patterns.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GLB-SCI+
Description: Participants will receive a combination of the prior interventions studied, with the goal of showing that a multi-component intervention will be the most effective in encouraging weight loss among participants with a spinal cord injury.
Study: NCT00706238

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A
Description: IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.
Study: NCT00555698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulations for Depression
Description: Deep Brain Stimulations for Depression
Study: NCT02510521

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acute muscle exercise by NMES

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: daily workout sequence with NMES in one week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rest situation
Study: NCT02178150

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01462370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Etoricoxib 120 mg tablet given orally for one dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib
Description: Etoricoxib 120 mg tablet given orally for one dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to etoricoxib
Description: Placebo to etoricoxib, one tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to etoricoxib
Description: Placebo to etoricoxib, one tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ibuprofen
Description: Placebo to ibuprofen, up to four 3-capsule doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to ibuprofen
Description: Placebo to ibuprofen, up to four 3-capsule doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
Description: Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
Description: Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
Study: NCT03813927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Supplementation with tablet 170 μg Vitamin each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with tablet 20 μg Vitamin each day.
Study: NCT00560352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m\^2 QD, 1.3 mg/m\^2 QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
Study: NCT02224807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Progressive Resistance Training (PRT) and a healthy diet
Description: no additional information; see arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: PRT and a healthy diet, plus weight loss
Description: no additional information, see arm description
Study: NCT03822117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib administered orally once daily (QD).
Study: NCT02178345

Intervention type: PROCEDURE
Intervention: diffusion weighted (DW) MRI

Intervention type: PROCEDURE
Intervention: diffusion weighted (DW) MRI

Intervention type: PROCEDURE
Intervention: dynamic contrast agent (DCE) MRI

Intervention type: PROCEDURE
Intervention: dynamic contrast agent (DCE) MRI
Study: NCT04500899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mydfrin
Description: A test dose of 20 mcg of Mydfrin will be administered through the peripheral intravenous line. BP will be monitored after each bolus of phenylephrine. Subsequent Mydfrin injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, however making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.